Skip to main content

Peer Review reports

From: Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort

Original Submission
18 Jan 2021 Submitted Original manuscript
4 Feb 2021 Author responded Author comments - Alexandre André Balieiro Anastácio da Costa
Resubmission - Version 2
4 Feb 2021 Submitted Manuscript version 2
22 Feb 2021 Reviewed Reviewer Report - Shoji Nagao
2 Mar 2021 Reviewed Reviewer Report
3 Mar 2021 Reviewed Reviewer Report
18 Mar 2021 Author responded Author comments - Alexandre André Balieiro Anastácio da Costa
Resubmission - Version 3
18 Mar 2021 Submitted Manuscript version 3
23 Mar 2021 Reviewed Reviewer Report
23 Mar 2021 Reviewed Reviewer Report - Shoji Nagao
28 Mar 2021 Author responded Author comments - Alexandre André Balieiro Anastácio da Costa
Resubmission - Version 4
28 Mar 2021 Submitted Manuscript version 4
13 Apr 2021 Reviewed Reviewer Report
23 Apr 2021 Reviewed Reviewer Report - Shoji Nagao
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
23 Apr 2021 Editorially accepted
8 May 2021 Article published 10.1186/s12885-021-08270-0

You can find further information about peer review here.

Back to article page